SCHEMBL15415417

SCHEMBL15415417

ClCc1nc2cc(Cl)ccc2n1C1CCOC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.40
PDE10A Q9Y233 2/20 0.39
GLP1R P43220 3/20 0.38
LRRK2 Q5S007 2/20 0.37
PIK3CB P42338 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CG P48736 1/20 0.36
CCR3 P51677 1/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
KCNH2 Q12809 2/20 0.35
HTR3A P46098 1/20 0.35
MCHR1 Q99705 2/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15415872 0.92 PDE10A (0.44) CYP11B2PDE10ALRRK2PIK3CBPIK3CA
SCHEMBL15416560 0.89 CYP11B2 (0.41) CYP11B2PIK3CBPIK3CAPIK3CGCCR3
SCHEMBL15416360 0.79 CYP11B2 (0.47) CYP11B2CCR3KCNH2MCHR1
SCHEMBL16763611 0.79 CYP11B2 (0.47) CYP11B2CCR3KCNH2MCHR1
SCHEMBL24165560 0.78 CYP11B2 (0.46) CYP11B2LRRK2CCR3KCNH2MCHR1
SCHEMBL16763370 0.77 CYP11B2 (0.43) CYP11B2CCR3KCNH2MCHR1JAK2
SCHEMBL18807889 0.77 CYP11B2 (0.43) CYP11B2CCR3ALDH1A1KCNH2MCHR1
SCHEMBL16512912 0.77 CCR3 (0.48) CYP11B2CCR3KCNH2MCHR1
SCHEMBL19470911 0.76 CYP11B2 (0.46) CYP11B2PDE10ACCR3ALDH1A1MCHR1
Hydrochloric Acid SCHEMBL16486357 0.76 CCR3 (0.47) CYP11B2CCR3KCNH2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872502-B1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2016-08-24 EP disclosed
US-20160200741-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2016-07-14 US disclosed
US-9206191-B2 Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2015-12-08 US disclosed
US-20150158879-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
EP-2872502-A1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2015-05-20 EP disclosed
WO-2014009302-A1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158879-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection ADORA3, ADORA1, BRS3 CYP11B2 526/4885PDE10A 4238/4885GLP1R 495/4885
US-20160200741-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection ADORA3, ADORA1, BRS3 CYP11B2 526/4885PDE10A 4238/4885GLP1R 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.